Genprex, INC 8-K filings

Genprex, Inc. has been formally notified that it has regained compliance with the Nasdaq Capital Market's Minimum Bid Price Requirement.

Genprex, Inc. announces a collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in non-small cell lung cancer clinical trials.

Genprex, Inc. has received an exception from the Nasdaq Hearings Panel to continue listing on The Nasdaq Capital Market, subject to specific bid price requirements through December 7, 2026.

Genprex, Inc. files an 8-K detailing a 1-for-22 reverse stock split effective July 16, 2026, and provides updates on its Acclaim-1 and Acclaim-3 clinical trials.

Genprex, Inc. announced that its stockholders approved an amended and restated equity incentive plan and elected directors at the 2026 Annual Meeting.

Genprex, Inc. received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price and intends to request a hearing.

Genprex, Inc. reported positive clinical data from studies of predictive biomarkers for its lead drug candidate, Reqorsa Gene Therapy, in lung cancer patients at the 2026 ASCO Annual Meeting.

Genprex, Inc. announced positive preclinical data for its diabetes gene therapy candidate, GPX-002, demonstrating reversal of hyperglycemia in Type 2 diabetic mouse models.

Genprex announced the Israel Patent Office granted a patent for its Reqorsa Gene Therapy in combination with PD-1 antibodies for cancer treatment, expanding its global IP portfolio.

Genprex announces positive preclinical data for its diabetes gene therapy candidate, GPX-002, demonstrating reversal of hyperglycemia in Type 2 diabetic mouse models.

Genprex has entered a new Sponsored Research Agreement with UT MD Anderson to study biomarkers for its lead drug candidate, Reqorsa, in lung cancer treatment.

Genprex, Inc. announced new patent grants in Japan and Europe for its Reqorsa Gene Therapy and provided an update on its Acclaim-3 clinical trial for small cell lung cancer.

Genprex, Inc. announced a key patent acceptance in Australia and the expansion of its Acclaim-3 clinical trial for extensive stage small cell lung cancer.

Genprex, Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, averting immediate delisting but entering a strict one-year monitoring period.

Genprex announces significant clinical program updates for its GPX-002 diabetes gene therapy, including preclinical study expansion and regulatory engagement.

Genprex, Inc. announced positive preliminary preclinical data for its GPX-002 gene therapy in Type 2 diabetic animal models, demonstrating beta cell rejuvenation and normalized glucose levels.

Genprex, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following recent capital raises, though Nasdaq's Panel has not yet made a final determination.

Genprex, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement and received an extension until December 31, 2025, to meet the minimum stockholders' equity requirement.

Genprex, Inc. filed a prospectus supplement to offer and sell up to an additional $75 million in common stock through its At-the-Market offering.

Genprex, Inc. announced the addition of a new clinical trial site and plans for further expansion for its lead drug candidate, Reqorsa Gene Therapy, in lung cancer studies.

Genprex, Inc. announced a U.S. patent grant for its lead drug candidate, Reqorsa Gene Therapy, in combination with PD-L1 antibodies, extending exclusivity through 2037.

Genprex, Inc. announced the European Patent Office's intent to grant a patent for its Reqorsa Gene Therapy combined with PD-1 antibodies for cancer treatment.

Genprex, Inc. announced a registered direct offering of common stock and concurrent private placement of warrants, expecting $3.4 million upfront and up to $6.6 million from warrant exercises.

Genprex announced positive preclinical data for its lead drug candidate, Reqorsa Gene Therapy, in ALK-EML4 positive non-small cell lung cancer.

Genprex, Inc. announced a registered direct offering raising $2.7 million, with potential for an additional $5.4 million from warrant exercises, as it works to regain Nasdaq listing compliance.

Genprex announced positive preclinical data for its lead drug candidate, Reqorsa Gene Therapy, in ALK-EML4 positive non-small cell lung cancer, demonstrating superior tumor shrinkage in combination therapy.

Genprex, Inc. has completed a one-for-fifty reverse stock split, reducing its outstanding shares to approximately 1 million.

Genprex, Inc. received a Nasdaq extension for listing compliance until October 31, 2025, and will implement a 1:50 reverse stock split to address bid price deficiencies, while also providing updates on its oncology and diabetes gene therapy programs.

Genprex, Inc. received a Nasdaq delisting notice due to non-compliance with minimum stockholders' equity and bid price requirements, but has requested a hearing to appeal.

Genprex announces patent allowances in the U.S. and Europe for Reqorsa gene therapy in combination with PD-L1 and PD-1 antibodies, respectively, with both patents expiring in 2037.